Eva Cernuda-Morollón
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eva Cernuda-Morollón has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Carlos López-Larrea
Translational Immunology, Instituto de Investigación Sanitaria del Principado de Asturias ISPA, 33011 Oviedo, Spain
2 shared publications - Esther Serrano-Pertierra
Department of Biochemistry & Institute of Biotechnology of Asturias, University of Oviedo, Oviedo, Spain
2 shared publications - Pedro Oliva Nacarino
Neurology Department Hospital Universitario Central de Asturias Oviedo Spain
2 shared publications - Alberto Tuñón
Neurology Department, Hospital Universitario Central de Asturias, C/ Aldea Cerdeño, s/n, 33011, Oviedo, Spain
1 shared publication - Babette Weksler
Weill Cornell Medical College, New York, NY, USA
1 shared publication - Beatriz Marcos-Ramiro
Department of Organic Chemistry School of Chemistry Universidad Complutense de Madrid Plaza de las Ciencias s/n 28040 Madrid Spain
1 shared publication
Latest Publications
- 1 May 2015
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 282, 39-44
Increased natural killer cell chemotaxis to CXCL12 in patients with multiple sclerosis
- 1 May 2015
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 282, 39-44
Increased natural killer cell chemotaxis to CXCL12 in patients with multiple sclerosis
- Open Access
- 22 September 2014
- Published by Springer Nature in BMC Neuroscience
- Vol. 15 (1) , 1-14
Microparticles in multiple sclerosis and clinically isolated syndrome: effect on endothelial barrier function
Cell-derived microparticles are secreted in response to cell damage or dysfunction. Endothelial and platelet dysfunction are thought to contribute to the development of multiple sclerosis (MS). Our aim here is, first, to compare the presence of microparticles of endothelial and platelet origin in plasma from patients with different clinical forms of MS and with clinically isolated syndrome. Second, to investigate the effect of microparticles on endothelial barrier function. Platelet-poor plasma from 95 patients (12 with clinically isolated syndrome, 51 relapsing-remitting, 23 secondary progressive, 9 primary progressive) and 49 healthy controls were analyzed for the presence of platelet-derived and endothelium-derived microparticles by flow cytometry. The plasma concentration of platelet-derived and endothelium-derived microparticles increased in all clinical forms of MS and in clinically isolated syndrome versus controls. The response of endothelial barriers to purified microparticles was measured by electric cell-substrate impedance sensing. Microparticles from relapsing-remitting MS patients induced, at equivalent concentrations, a stronger disruption of endothelial barriers than those from healthy donors or from patients with clinically isolated syndrome. MS microparticles acted synergistically with the inflammatory mediator thrombin to disrupt the endothelial barrier function. Plasma microparticles should be considered not only as markers of early stages of MS, but also as pathological factors with the potential to increase endothelial permeability and leukocyte infiltration.
- 22 September 2014
- Published by Springer Nature in BMC Neuroscience
- Vol. 15 (1) , 1-14
Open AccessMicroparticles in multiple sclerosis and clinically isolated syndrome: effect on endothelial barrier function
Cell-derived microparticles are secreted in response to cell damage or dysfunction. Endothelial and platelet dysfunction are thought to contribute to the development of multiple sclerosis (MS). Our aim here is, first, to compare the presence of microparticles of endothelial and platelet origin in plasma from patients with different clinical forms of MS and with clinically isolated syndrome. Second, to investigate the effect of microparticles on endothelial barrier function. Platelet-poor plasma from 95 patients (12 with clinically isolated syndrome, 51 relapsing-remitting, 23 secondary progressive, 9 primary progressive) and 49 healthy controls were analyzed for the presence of platelet-derived and endothelium-derived microparticles by flow cytometry. The plasma concentration of platelet-derived and endothelium-derived microparticles increased in all clinical forms of MS and in clinically isolated syndrome versus controls. The response of endothelial barriers to purified microparticles was measured by electric cell-substrate impedance sensing. Microparticles from relapsing-remitting MS patients induced, at equivalent concentrations, a stronger disruption of endothelial barriers than those from healthy donors or from patients with clinically isolated syndrome. MS microparticles acted synergistically with the inflammatory mediator thrombin to disrupt the endothelial barrier function. Plasma microparticles should be considered not only as markers of early stages of MS, but also as pathological factors with the potential to increase endothelial permeability and leukocyte infiltration.